Legal & General Group
RARE icon

Legal & General Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Legal & General Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Buy
590,294
+179,021
+44% +$4.03M ﹤0.01% 1027
2025
Q4 		$9.46M Buy
411,273
+8,458
+2% +$278K ﹤0.01% 1195
2025
Q3 		$12.1M Buy
402,815
+89,011
+28% +$2.67M ﹤0.01% 1108
2025
Q2 		$11.4M Buy
313,804
+54,837
+21% +$1.98M ﹤0.01% 1120
2025
Q1 		$9.38M Buy
258,967
+160,235
+162% +$6.67M ﹤0.01% 1161
2024
Q4 		$4.15M Buy
98,732
+5,896
+6% +$293K ﹤0.01% 1666
2024
Q3 		$5.16M Buy
92,836
+7,461
+9% +$380K ﹤0.01% 1558
2024
Q2 		$3.51M Buy
85,375
+1,506
+2% +$64.3K ﹤0.01% 1708
2024
Q1 		$3.92M Buy
83,869
+11,037
+15% +$521K ﹤0.01% 1635
2023
Q4 		$3.48M Buy
72,832
+3,899
+6% +$151K ﹤0.01% 1694
2023
Q3 		$2.46M Sell
68,933
-37,978
-36% -$1.5M ﹤0.01% 1803
2023
Q2 		$4.93M Sell
106,911
-7,423
-6% -$344K ﹤0.01% 1464
2023
Q1 		$4.58M Buy
114,334
+25,213
+28% +$1.08M ﹤0.01% 1460
2022
Q4 		$4.13M Buy
89,121
+4,638
+5% +$182K ﹤0.01% 1510
2022
Q3 		$3.5M Buy
84,483
+7,314
+9% +$376K ﹤0.01% 1563
2022
Q2 		$4.6M Buy
77,169
+2,269
+3% +$140K ﹤0.01% 1450
2022
Q1 		$5.44M Buy
74,900
+5,636
+8% +$392K ﹤0.01% 1475
2021
Q4 		$5.83M Buy
69,264
+3,513
+5% +$286K ﹤0.01% 1488
2021
Q3 		$5.93M Buy
65,751
+16,133
+33% +$1.46M ﹤0.01% 1455
2021
Q2 		$4.73M Buy
49,618
+29
+0.1% +$3.02K ﹤0.01% 1561
2021
Q1 		$5.65M Sell
49,589
-528
-1% -$71.9K ﹤0.01% 1502
2020
Q4 		$6.94M Buy
50,117
+5,856
+13% +$695K ﹤0.01% 1309
2020
Q3 		$3.64M Sell
44,261
-2,805
-6% -$233K ﹤0.01% 1503
2020
Q2 		$3.68M Buy
47,066
+7,875
+20% +$521K ﹤0.01% 1450
2020
Q1 		$1.74M Sell
39,191
-2,557
-6% -$133K ﹤0.01% 1647
2019
Q4 		$1.78M Buy
41,748
+6,692
+19% +$276K ﹤0.01% 1855
2019
Q3 		$1.5M Buy
35,056
+4,417
+14% +$240K ﹤0.01% 1843
2019
Q2 		$1.95M Buy
30,639
+843
+3% +$53.7K ﹤0.01% 1704
2019
Q1 		$2.07M Buy
29,796
+9,109
+44% +$520K ﹤0.01% 1687
2018
Q4 		$899K Buy
20,687
+3,308
+19% +$181K ﹤0.01% 1937
2018
Q3 		$1.33M Buy
17,379
+1,403
+9% +$114K ﹤0.01% 1867
2018
Q2 		$1.23M Sell
15,976
-4,450
-22% -$287K ﹤0.01% 1856
2018
Q1 		$1.04M Sell
20,426
-131,906
-87% -$6.64M ﹤0.01% 1873
2017
Q4 		$7.07M Buy
152,332
+134,407
+750% +$6.59M 0.01% 916
2017
Q3 		$957K Buy
17,925
+2,843
+19% +$168K ﹤0.01% 1880
2017
Q2 		$933K Buy
15,082
+2,212
+17% +$133K ﹤0.01% 1849
2017
Q1 		$870K Buy
12,870
+448
+4% +$34.1K ﹤0.01% 1845
2016
Q4 		$873K Buy
12,422
+5,010
+68% +$355K ﹤0.01% 1792
2016
Q3 		$516K Sell
7,412
-807
-10% -$51.5K ﹤0.01% 1679
2016
Q2 		$402K Hold
8,219
– – ﹤0.01% 1437
2016
Q1 		$502K Buy
8,219
+1,063
+15% +$69.6K ﹤0.01% 1310
2015
Q4 		$802K Hold
7,156
– – ﹤0.01% 1211
2015
Q3 		$664K Buy
7,156
+706
+11% +$80.8K ﹤0.01% 1225
2015
Q2 		$641K Buy
6,450
+4,071
+171% +$316K ﹤0.01% 1254
2015
Q1 		$151K Buy
2,379
+1,078
+83% +$59.9K ﹤0.01% 1799
2014
Q4 		$58K Hold
1,301
– – ﹤0.01% 2346
2014
Q3 		$76K Buy
+1,301
New +$65.5K ﹤0.01% 2104

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Legal & General Group's RARE Position: Q1 2026 in Review

Legal & General Group increased its Ultragenyx Pharmaceutical (RARE) stake by 44% in Q1 2026, buying an estimated $4.03M and bringing the position to 590,294 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1027.

Legal & General Group first reported a position in RARE in Q3 2014 and has held it in 47 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Legal & General Group held 590,294 shares of Ultragenyx Pharmaceutical worth $12.4M as of Q1 2026.
  • Legal & General Group bought 179,021 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.03M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1027 holding.
  • Legal & General Group first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and has held it in 47 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.